Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients

Abstract High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT) is still a consolidation treatment choice for relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL) patients and some aggressive B-cell NHL as frontline therapy. Due to the shortage of carmustine,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chen Tian, Yueyang Li, Su Liu, Zehui Chen, Yizhuo Zhang, Yong Yu, Hongliang Yang, Haifeng Zhao, Zhigang Zhao, Tian Yuan, Yafei Wang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/c16017e1730f4917868c441896b63577
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c16017e1730f4917868c441896b63577
record_format	dspace
spelling	oai:doaj.org-article:c16017e1730f4917868c441896b635772021-12-02T12:11:52ZModified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients10.1038/s41598-021-81944-82045-2322https://doaj.org/article/c16017e1730f4917868c441896b635772021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-81944-8https://doaj.org/toc/2045-2322Abstract High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT) is still a consolidation treatment choice for relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL) patients and some aggressive B-cell NHL as frontline therapy. Due to the shortage of carmustine, we switched to idarubicin-substituted BEAC (IEAC) conditioning regimen. We retrospectively compared the outcomes of 72 aggressive B-cell NHL patients treated with IEAC or BEAC regimens followed by ASCT as upfront consolidative treatment. The median time to neutrophil and platelet reconstitution showed no difference between IEAC and BEAC groups. IEAC regimen was well tolerated without increase of adverse events. Transplant-related mortality didn’t occur. The overall survival (OS) and progression-free survival (PFS) of IEAC group (33 and 23 months) were a little longer than that of BEAC group (30 and 18 months). However, due to the small sample numbers, there’s no significant difference in OS and PFS between IEAC and BEAC group with DLBCL or MCL. Multivariate analysis showed that AnnArbor staging, IPI score, lactate dehydrogenase level, remission of disease, modified regimen were related with PFS and OS. In conclusion, IEAC regimen was well tolerated and replacement with idarubicin could be an alternative when carmustine was not available.Chen TianYueyang LiSu LiuZehui ChenYizhuo ZhangYong YuHongliang YangHaifeng ZhaoZhigang ZhaoTian YuanYafei WangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Chen Tian Yueyang Li Su Liu Zehui Chen Yizhuo Zhang Yong Yu Hongliang Yang Haifeng Zhao Zhigang Zhao Tian Yuan Yafei Wang Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients
description	Abstract High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT) is still a consolidation treatment choice for relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL) patients and some aggressive B-cell NHL as frontline therapy. Due to the shortage of carmustine, we switched to idarubicin-substituted BEAC (IEAC) conditioning regimen. We retrospectively compared the outcomes of 72 aggressive B-cell NHL patients treated with IEAC or BEAC regimens followed by ASCT as upfront consolidative treatment. The median time to neutrophil and platelet reconstitution showed no difference between IEAC and BEAC groups. IEAC regimen was well tolerated without increase of adverse events. Transplant-related mortality didn’t occur. The overall survival (OS) and progression-free survival (PFS) of IEAC group (33 and 23 months) were a little longer than that of BEAC group (30 and 18 months). However, due to the small sample numbers, there’s no significant difference in OS and PFS between IEAC and BEAC group with DLBCL or MCL. Multivariate analysis showed that AnnArbor staging, IPI score, lactate dehydrogenase level, remission of disease, modified regimen were related with PFS and OS. In conclusion, IEAC regimen was well tolerated and replacement with idarubicin could be an alternative when carmustine was not available.
format	article
author	Chen Tian Yueyang Li Su Liu Zehui Chen Yizhuo Zhang Yong Yu Hongliang Yang Haifeng Zhao Zhigang Zhao Tian Yuan Yafei Wang
author_facet	Chen Tian Yueyang Li Su Liu Zehui Chen Yizhuo Zhang Yong Yu Hongliang Yang Haifeng Zhao Zhigang Zhao Tian Yuan Yafei Wang
author_sort	Chen Tian
title	Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients
title_short	Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients
title_full	Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients
title_fullStr	Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients
title_full_unstemmed	Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients
title_sort	modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive b-cell non-hodgkin’s lymphoma patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/c16017e1730f4917868c441896b63577
work_keys_str_mv	AT chentian modifiedconditioningregimenwithidarubicinfollowedbyautologoushematopoieticstemcelltransplantationforinvasivebcellnonhodgkinslymphomapatients AT yueyangli modifiedconditioningregimenwithidarubicinfollowedbyautologoushematopoieticstemcelltransplantationforinvasivebcellnonhodgkinslymphomapatients AT suliu modifiedconditioningregimenwithidarubicinfollowedbyautologoushematopoieticstemcelltransplantationforinvasivebcellnonhodgkinslymphomapatients AT zehuichen modifiedconditioningregimenwithidarubicinfollowedbyautologoushematopoieticstemcelltransplantationforinvasivebcellnonhodgkinslymphomapatients AT yizhuozhang modifiedconditioningregimenwithidarubicinfollowedbyautologoushematopoieticstemcelltransplantationforinvasivebcellnonhodgkinslymphomapatients AT yongyu modifiedconditioningregimenwithidarubicinfollowedbyautologoushematopoieticstemcelltransplantationforinvasivebcellnonhodgkinslymphomapatients AT hongliangyang modifiedconditioningregimenwithidarubicinfollowedbyautologoushematopoieticstemcelltransplantationforinvasivebcellnonhodgkinslymphomapatients AT haifengzhao modifiedconditioningregimenwithidarubicinfollowedbyautologoushematopoieticstemcelltransplantationforinvasivebcellnonhodgkinslymphomapatients AT zhigangzhao modifiedconditioningregimenwithidarubicinfollowedbyautologoushematopoieticstemcelltransplantationforinvasivebcellnonhodgkinslymphomapatients AT tianyuan modifiedconditioningregimenwithidarubicinfollowedbyautologoushematopoieticstemcelltransplantationforinvasivebcellnonhodgkinslymphomapatients AT yafeiwang modifiedconditioningregimenwithidarubicinfollowedbyautologoushematopoieticstemcelltransplantationforinvasivebcellnonhodgkinslymphomapatients
_version_	1718394597794643968

Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients

Ejemplares similares